Stoke Therapeutics, Inc. (STOK) Stock Analysis
A live, multi-source view of Stoke Therapeutics, Inc. (STOK): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016.
Sector: Healthcare · Industry: Biotechnology · United States · 170 employees · stoketherapeutics.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Stoke Therapeutics, Inc. (STOK) had a market capitalization of $1.92B (forward -8.5) and a beta of 1.23; the shares traded in a 52-week range of $20.32 – $40.22 (35.6% over the year).
- Market cap
- $1.92B
- Enterprise value
- $1.63B
- Forward P/E
- -8.5
- Price / book
- 5.38
- EPS (trailing)
- $-3.37
- EPS (forward)
- $-3.52
- Payout ratio
- 0.0%
- 52-week range
- $20.32 – $40.22
- 52-week change
- 35.6%
- Beta
- 1.23
- Average volume
- 875,958
- Shares outstanding
- 64.5M
- Short % of float
- 20.89%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Stoke Therapeutics, Inc. (STOK) last closed at $29.34 (the last completed close before that scan).
Technicals at the scan: RSI 38 (neutral territory), price -6.6% versus its 20-day average, 20-day versus 50-day average spread +1.4%, MACD histogram -0.34.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 79/100.
Next scheduled company event: in 53 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of STOK; corporate insiders filed 0 buys and 10 sells (3 distinct filers, latest disclosure 2026-09-03). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Barry Ticho (0B/6S), Jonathan Allan (0B/2S), Kaye Edward M. Md (0B/2S). Who is trading what
RapidTradeView pick record
STOK has been a daily pick 1 time. Most recent: 2026-09-09, rank #3, still grading. Full scoreboard
What this page covers
RapidTradeView pulls Stoke Therapeutics, Inc. (STOK) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell STOK.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.